Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

NeoPharm moves LED to phase I for prostate cancer

Oct. 22, 1997

Pharmacyclics enters into licensing agreement with Nycomed for Lu-Tex

Oct. 21, 1997

Potential new anticancer vaccines described

Oct. 21, 1997

Yale-Vion developing bacteria-based cancer treatment

Oct. 21, 1997

Peptech reaches phase I goals for antagonist G; exercises license option

Oct. 20, 1997

ImClone and CombiChem enter alliance for drug discovery in oncology

Oct. 20, 1997

Agouron to collaborate with U.K. organizations in search for anticancer drugs

Oct. 17, 1997

Health Research claims peptide inhibitor of growth factors

Oct. 17, 1997

S-1: pharmacokinetics of components in rats after single and multiple oral doses

Oct. 16, 1997

Nycomed licenses new anthracycline from Anthra

Oct. 16, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...